Overview

Gender

male

Investor Type

Investment Partner

Ed Mathers joined NEA as a partner in August 2008 after a successful 26 years in the biopharm industry. Prior to joining NEA, Ed Mathers served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc, where he was responsible for leading the company's venture capital subsidiary, and all business and corporate development activities. In addition, Ed Mathers was an integral member of the executive team that led to the sale of MedImmune to Astra Zeneca in 2007.

Prior to joining MedImmune, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Ed Mathers spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline) in a variety of commercial roles, and started his career at Ortho Pharmaceuticals Corporation, an operating company of Johnson & Johnson. Ed Mathers currently sits on the Boards of Directors of Intarcia Therapeutics, Inc., Satori Therapeutics and Plexxikon Inc.

He earned his bachelor's degree in chemistry from North Carolina State University.